BUSINESS

• Oncodesign, Veritas Form Collab for mRNA Drug Development
  May 24, 2023

• Lecanemab Filed in UK, Designated under Innovative Pathway: Eisai/Biogen
  May 23, 2023

• Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
  May 22, 2023

• Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
  May 22, 2023

• Mounjaro No. 1 in GP Promotion in March, Dayvigo Most Detailed for HPs
  May 22, 2023

• Nipro’s Nexium AG Grabs 53% Market Share in Just 4 Months
  May 22, 2023

• Daiichi Sankyo Begins Japan PIII for Omicron-Tailored Jab
  May 22, 2023

• Top 4 Wholesalers on Solid Note with 30% Operating Profit Rise in FY2022
  May 19, 2023

• Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
  May 19, 2023

• Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
  May 19, 2023

• BMS Files Luspatercept for MDS Associated Anemia in Japan
  May 19, 2023

• Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
  May 18, 2023

• Xocova Makes Up 11% of COVID Oral Drug Prescriptions Filled Outside Pharmacies
  May 18, 2023

• Santen Set to Thwart Post-Launch Challenges Expected for Myopia Drug Hopefuls: President
  May 18, 2023

• Takeda’s cTTP Therapy Gets Priority Review in US
  May 18, 2023

• Lecanemab Accepted for Review by Canadian Authorities: Eisai/Biogen
  May 18, 2023

• Sony, Astellas Ink Research Deal for ADC Discovery Using Linker Technology
  May 17, 2023

• Nonprescription Obesity Med Unlikely to Hit Japan Market Until Next Year
  May 17, 2023

• Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
  May 17, 2023

• Kenzo Sawai to Quit Group Management to Focus on Advocacy
  May 16, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 135
• 136
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• …
• Next ›
• 最終 »